Format

Send to

Choose Destination
See comment in PubMed Commons below
Cold Spring Harb Perspect Med. 2013 Nov 1;3(11). pii: a015552. doi: 10.1101/cshperspect.a015552.

Regulatory T-cell therapy in transplantation: moving to the clinic.

Author information

1
Department of Surgery, University of California, San Francisco, San Francisco, California 94143.

Abstract

Regulatory T cells (Tregs) are essential to transplantation tolerance and their therapeutic efficacy is well documented in animal models. Moreover, human Tregs can be identified, isolated, and expanded in short-term ex vivo cultures so that a therapeutic product can be manufactured at relevant doses. Treg therapy is being planned at multiple transplant centers around the world. In this article, we review topics critical to effective implementation of Treg therapy in transplantation. We will address issues such as Treg dose, antigen specificity, and adjunct therapies required for transplant tolerance induction. We will summarize technical advances in Treg manufacturing and provide guidelines for identity and purity assurance of Treg products. Clinical trial designs and Treg manufacturing plans that incorporate the most up-to-date scientific understanding in Treg biology will be essential for harnessing the tolerogenic potential of Treg therapy in transplantation.

PMID:
24186492
PMCID:
PMC3808774
DOI:
10.1101/cshperspect.a015552
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center